Early cognitive function tests predict early progression in glioblastoma
Authors:
- Soon-Tae LeeSLSoon-Tae Lee
- Chul-Kee ParkCPChul-Kee Park
- Jin Wook KimJKJin Wook Kim
- Min-Jung ParkMPMin-Jung Park
- Hyon LeeHLHyon Lee
- Jung-Ah LimJLJung-Ah Lim
- Seung Hong ChoiSCSeung Hong Choi
- Tae Min KimTKTae Min Kim
- Se-Hoon LeeSLSe-Hoon Lee
- Sung-Hye ParkSPSung-Hye Park
- Il Han KimIKIl Han Kim
- Kyoung-Min LeeKLKyoung-Min Lee
Open Access
- 12 May 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 2 (3) , 137-143
Abstract
Early progression of glioblastoma prevents patients from completing the standard chemoradiation protocol. Given that cognitive function is associated with prognosis in glioblastoma, we investigated the usefulness of preoperative cognitive function tests for predicting the early progression of glioblastoma. Consecutive patients who underwent glioma surgery were preoperatively evaluated with cognitive function tests including the Mini Mental State Examination, digit span tests, the Controlled Oral Word Association Test, the Trail Making Tests (TMT, parts A, B, and C), and the Stroop test. Glioblastomas were treated with a standard protocol using radiation and temozolomide, and 6-month progression-free survival (PFS-6) was analyzed retrospectively. Among 126 patients who underwent glioma surgery, 55 patients were diagnosed with glioblastoma, and 50 patients were eligible for the PFS-6 analysis. Thirty-four patients (68%) achieved PFS-6. No significant differences were observed in demographics or tumor characteristics between patients without progression (PFS-6) or patients with progression (no-PFS-6). In the cognitive function tests, the PFS-6 patients exhibited better performance in TMT-A and TMT-B. In a multivariate logistic regression, TMT-B was the only independent predictor for PFS-6, whereas age, years of education, gross total or near total resection, concomitant chemoradiation, and TMT-A were not predictors. Patients with good TMT-B performance exhibited better early prognosis in the Kaplan-Meier survival analysis and had better recursive partitioning analysis classes. Our results indicated that preoperative TMTs can be useful for rapid evaluation of early prognosis in patients with glioblastoma.Keywords
This publication has 26 references indexed in Scilit:
- NT-40 * Interim Analysis of the EF-14 Trial: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBMNeuro-Oncology, 2014
- Early measures of cognitive function predict survival in patients with newly diagnosed glioblastomaNeuro-Oncology, 2012
- Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for GlioblastomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- The course of neurocognitive functioning in high-grade glioma patients1Neuro-Oncology, 2007
- Detrimental Effects of Tumor Progression on Cognitive Function of Patients With High-Grade GliomaJournal of Clinical Oncology, 2006
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Cognitive deficits in adult patients with brain tumoursThe Lancet Neurology, 2004
- Neurobehavioral Status and Health-Related Quality of Life in Newly Diagnosed High-Grade Glioma PatientsJournal of Clinical Oncology, 2001